Drug Database
VA
valproate sodium (K828SP / Selenica R)
✓ ApprovedKowa · SCN1A · Small Molecule
What is valproate sodium?
valproate sodium is a small molecule developed by Kowa. It is approved for therapeutic indications via oral (po).
Drug Profile
| Brand Names | K828SP, Selenica R |
| Company | Kowa |
| Drug Class | Small Molecule |
| Molecular Target | SCN1A, SCN2A, SCN3A |
| Route | Oral (PO) |
| Status | Approved |
Sources: ClinicalTrials.gov, Kowa
Mechanism of Action
Molecular Targets
valproate sodium acts on 3 molecular targets:
| SCN1A | sodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3) |
| SCN2A | sodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS) |
| SCN3A | sodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Therapeutic Indications
valproate sodium is developed for 2 unique indications across 2 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Nervous system disorders | Epilepsy | ✓ Approved |
| Congenital, familial and genetic disorders | Spinal muscular atrophy | Phase III |
Related Research Articles
Unable to load articles right now.